Von Hippel-Lindau (VHL) disease is a tumor syndrome that frequently involves the central nervous system (CNS). It is caused by germline mutation of the VHL gene. Subsequent VHL inactivation in selected cells is followed by numerous well-characterized molecular consequences, in particular, activation and stabilization of hypoxia-inducible factors HIF1 and HIF2. The link between VHL gene inactivation and tumorigenesis remains poorly understood. Hemangioblastomas are the most common manifestation in the CNS; however, CNS invasion by VHL disease-associated endolymphatic sac tumors or metastatic renal cancer also occur, and their differentiation from primary hemangioblastoma may be challenging. Finally, in this review, we present recent morphologic insights on the developmental concept of VHL tumorigenesis which is best explained by pathologic persistence of temporary embryonic progenitor cells.
Introduction
Von Hippel-Lindau (VHL) disease is an autosomal dominant disorder that is caused by germline mutations in the tumor suppressor gene VHL on chromosome 3p25 (1, 2) . It is characterized by frequent development of selective tumor types in specific topographic locations. Among others, central nervous system (CNS) hemangioblastoma and clear cell renal cell carcinoma (RCC) are the most consistently encountered tumors (3) .
Tumorigenesis in VHL syndrome is linked to the loss of VHL tumor suppressor protein function in cell differentiation (4) (5) (6) (7) .The loss of protein function is the result of a second genetic "hit" which inactivates the wild type VHL allele (8) . Subsequent to VHL gene inactivation and loss of VHL protein function, hypoxia-inducible factors (HIF1 and HIF2) are activated (9) (10) (11) . HIF1 is a heterodimer transcription factor composed of HIF1α and HIF1β subunits (12) . Through conditional transcriptional activation of effectors controlling vascularization, glucose metabolism and cell differentiation, HIF1 plays an important role in cellular response to oxygen changes (12) . HIF2α (also known as endothelial PAS domain-containing protein -1 (EPAS1)) is another hypoxia-inducible factor that functions as an integral component of transcription factors involved in the body response to low oxygen level (13) . In comparison to HIF1α which is expressed ubiquitously, HIF2α has a restricted tissue distribution and is expressed primarily in the vasculature of early developing embryo and subsequently in the lung, kidney interstitial cells, liver parenchyma, and neural crest cells (14) .
VHL protein is part of a multiprotein complex that targets HIFα subunits for ubiquitin-mediated degradation in proteasomes (11, (15) (16) (17) (18) (19) . In hypoxic conditions or with VHL biallelic inactivation, both HIF1α and HIF2α subunits will evade degradation, accumulate in the cell and complex with other subunits to form functional proteins (9, 10, 20) . The consequences of HIF1α and HIF2α up-regulation are multifaceted. One major change includes the transcriptional activation of genes containing hypoxia responsive elements. VEGF is among the target genes that will be overexpressed leading to enhanced angiogenesis and oxygen delivery (12, 21) . Additionally, HIF2α up-regulation is linked to enhanced dysregulated erythropoiesis while HIF2α deletion has been shown to result in anemia associated with decreased expression of erythropoietin (22, 23) .
Despite the significant alterations at the cellular and molecular levels in association with VHL silencing, it has remained unclear, however, why loss of VHL function and subsequent HIF activation lead to tumorigenesis. Molecular and structural analogies of tumor cells with developmental tissues (6, 14, 24, 25) have led to revisitation of the hypothesis of a developmental origin of VHL diseaseassociated tumors (26, 27) . There is increasing evidence that the "second hit" causes loss of pivotal VHL function during organ development leading to maldeveloped structures that represent prerequisites for tumor formation (28).
In VHL disease, the CNS is predominantly affected by hemangioblastic tumorigenesis, but may also be involved by endolymphatic sac tumors (ELST) or metastatic disease.
Hemangioblastomas
Hemangioblastomas of the nervous system are present in 80% of VHL patients and represent a defining feature of VHL syndrome (3, 29) . Topographic distribution of these tumors show a consistent pattern with the retina, cerebellum, brainstem and dorsal spinal cord being the most frequently involved locations (3) . With recent advancements in sensitive imaging techniques, there has been a shift in the distribution of these tumors with increasing proportion of spinal tumors in comparison to the pre MRI era (30). Supratentorial tumors represent less than 3% of all tumors in most series (30, 31). In contrast to sporadic hemangioblastomas, VHL patients frequently have multiple hemangioblastomas, as is the case in 127 out of 160 patients in one report (30).
Clinical and radiological presentation
Hemangioblastomas are benign tumors with no metastatic potential. However, as with other space occupying lesions of the brain, they may cause neurological deficit and carry a significant mortality rate if left untreated due to hydrocephalus, tonsillar herniation and brainstem compression (29, 32). Not infrequently, these tumors have an associated pseudocyst or syrinx evident by magnetic resonance imaging (MRI) (33) (Figure 1 ). In addition to this cystic component, which may be much larger than the tumor itself, these tumors have a typical MRI appearance of densely contrast-enhancing solid mass with smooth margins (30, 34, 35) .
Pathological features
The gross appearance of these tumors commonly shows a solid nodule with an associated pseudocyst. Pseudocysts result from secretory tumoral activity (33) and disappear after successful surgical removal of the tumoral nodule (33). The tumoral nodule is usually soft with bright or dark red color, and occasional yellow areas seen upon sectioning (28). Histological findings vary greatly and are dependent on tumor size (25) . There are two main cellular constituents of hemangioblastomas, "stromal" cells and vascular cells. By selective genetic analysis, "stromal" cells have been shown to be neoplastic cells (36, 37) . The origin of the "stromal" cell has been controversial (38) ; however, most consistently proposed has been a (25) . In the aforementioned study, all tumors smaller than 8 mm 3 showed exclusive reticular structure, also known as "angiomatotic", or "mesenchymal", that is characterized by small loosely scattered tumor cells separated by extensive vascularization (25) . Larger tumors reveal additional phenotypic change, neoplastic stromal cells that are enlarged in size with abundant cytoplasm and large nuclei, and frequently clustered in groups (25) . Cytologically, the stromal cells in these latter neoplasms may have an abundant glycogen or lipid-rich cytoplasm imparting a clear appearance of the cell on routine H&E sections. Foci of extramedullary erythropoiesis can be detected in cellular (epitheloid) areas, but are not detected in reticular (mesenchymal) tumor portions. It has therefore been postulated that reticular lesions represent an earlier stage of tumorigenesis from which epitheloid tumor with extramedullary erythropoiesis may develop (25) . Interestingly, these morphologic changes within individual hemangioblastomas have previously been interpreted as different stages of embryonic hemangioblastic maturation (40) .
Endolymphatic Sac Tumors
The endolymphatic duct/sac system is composed of single-lumen thin long endolymphatic duct ending in a short pouch-like endolymphatic sac (61) . The interior of this system is lined by singlelayered cuboidal endolymphatic duct/sac epithelium (62) . The intraossesous part of the endolymphatic duct/sac system is also referred to as the vestibular aqueduct (63) and represents the site of origin of ELST (64). The endolymphatic duct/sac system is part of the nonsensory membranous labyrinth of the inner ear with a potential functional role in maintenance of homeostasis and pressure of the inner ear, phagocytosis of debris and immunologic functions (65-68).
Epidemiology
ELST was first established as a distinct pathologic entity by Heffner in 1989 (69). However, ELST had not been recognized as 
Clinical presentation
ELST can cause hearing loss, tinnitus, vertigo and facial nerve paresis (75) . Hearing loss can occur in larger tumors with invasion of the otic capsule, but also in smaller tumors. The proposed mechanisms of hearing loss in these tumors include hemorrhage and/or endolymphatic hydrops (76, 77) .
Morphology
ELSTs present grossly as bright or dark red soft tissue masses (76 (Figure 2 ). Immunohistochemical analysis of VHL disease-associated ELSTs reveals positive immunoreactivity with anti-NSE, anti-MAK6, and anti-AE1/AE3 (64, 78). Immunohistochemistry for EMA and S100 is positive in subsets of cases (79) . Some sporadic tumors have also been reported to be positive for GFAP and vimentin (78) .
In addition to frank tumors, multifocal microscopic cystic and papillary structures were identified in the intra-and extraosseous endolymphatic duct/sac system in VHL patients (64). These structure were different in their molecular profile from similar cystic proliferations identified in non VHL patients; in VHL patients, the cystic and papillary structures showed loss of the wild-type VHL allele in addition to positive nuclear staining for HIF1 and HIF2 and expression of target proteins CAIX and GLUT-1 (64, 80). It has been proposed that these structures represent tumor precursors (64). Immunohistochemistry is a valuable tool to distinguish hemangioblastoma from metastatic RCC. Epithelial membrane antigen (EMA) was originally described to selectively identify RCC (81, 82) . However, focal expression of EMA may rarely occur in hemangioblastoma (83) (Figure 3) . Antiinhibin A showed a high sensitivity and specificity for hemangioblastoma in one study (84). Other potentially useful markers include anti-CD10 for the identification of RCC and D2-40 and aquaporin-1 for the selective identification of hemangioblastoma (85) (86) (87) (88) . More recently, a combination of PAX-2 and PAX8 (positive in RCC) and inhibin A (positive in hemangioblastoma) has been proposed as the most useful panel of markers to resolve this differential diagnosis (89) . Another important role of immunohistochemistry is the identification tumor heterogeneity that is caused by tumor metastasis into hemangioblastoma which is being reported in up to 8% of hemangioblastomas (90, 91) .
Metastasis

VHL tumorigenesis
Development of tumors in VHL diseaseArvid Lindau's hypothesis
Decades ago, the hypothesis of a hemangioblastic nature of CNS tumors in VHL disease fueled an even older debate on the origin of cancer which notably has not been settled until today. In the early and mid-1800s, Joseph Recamier and Robert Remak both noted that cancer tissue resembled embryonic tissue (92) . In 1874-1875 Francesco Durante and Julius Cohnheim proposed cancer to originate from small collections of embryonal cells that persist and do not differentiate into mature adult tissue (92) (93) (94) . In the early 1900s, this theory was rejected (92, 95, 96) .
When, however, Arvid Lindau discovered and described in detail the gross and histologic changes of VHL disease, he came to the conclusion that "…all types of neoplasia might be explained by a disturbed balance during mesodermal development during the third month of embryonal life" (26) . While Arvid Lindau was therefore a strong supporter of the "embryonic rest"-hypothesis to explain CNS tumorigenesis in VHL disease, he subsequently noted that "an underlying early maldevelopment" may give rise to two 
Lindau's hypothesis -analytical and experimental evidence
More recently, we worked on a resolution of this seemingly contradictory nature of VHL disease-associated CNS tumors. Key strategy for this effort was to change the primary target of histologic analysis. Instead of analyzing tumor tissues, we analyzed normal-appearing tissues of VHL patients in which tumors are known to frequently occur, spinal cord and cerebellum.
The study of tumor-free central and peripheral nervous system tissue of VHL patients revealed numerous microscopic structures that are not encountered in similar tissues of non-VHL control patients (24, 64, 97, 98) (Figure 4 ). In essence, these structures represent the "early embryonal maldevelopment" postulated by Lindau and have hence been designated "developmentally arrested structural elements" (DASEs) (97) . DASEs represent precursors of CNS tumors in VHL disease; however, only a small number of DASEs progress to frank tumor during the lifetime of a VHL patient (24, 25, 97 (24, 97, 98) (Figure 4) . Early tumor arising from DASEs is highly vascularized and resembles "angiomatosis". Upon further tumor growth, tumor cells increase in size, develop epitheloid architecture and may differentiate in blood (25, 42, 58) . The morphologic sequence of tumorigenesis from DASEs to frank tumor reveals transition of mesenchymal cells into epitheloid structures and thus explains the diverse and complex histologic presentation of CNS tumor in VHL disease.
According to Knudson's two hit hypothesis, tumorigenesis in VHL disease is initiated by the "second hit", inactivation of the wild type copy of the VHL allele in patients that carry the VHL mutation (8) . The recent identification of numerous VHL-deficient DASEs in tumor-free CNS tissues of VHL patients led to the conclusion that the "second hit" is necessary, but insufficient for tumorigenesis (98, 99) . Instead, "second hits" appear to be capable of producing DASEs from which frank tumors may or may not develop. The nature of the third hit allowing DASEs to develop into frank tumor remains unknown.
Persistence of temporary embryonal progenitor cells
In VHL disease, the embryonal rest hypothesis does not necessarily imply the generation of neoplastic tissue during organ development. Instead, it implies the causative genetic hit to occur during organ development with the effect of developmental arrest of variable numbers of embryonal/fetal cells that have the capacity of eventual neoplastic proliferation. Key arguments are: a) Organ selectivity: Precursor and tumor formation occurs abundantly in selective tissue structures, and not at all in others; In VHL disease, there is dramatically increased risk of development of hemangioblastoma, renal clear cell carcinoma, cystadenoma of pancreas and endolymphatic sac, and neuroendocrine tumors, but no increased risk for any other type of cancer. Although not definitively demonstrated, there is strong supportive evidence for hemangioblastic differentiation to occur during brain (and even stronger evidence for kidney) development. Hemangioblastic cells are not part of the mature nervous system; instead, hemangioblastic cells persist in the nervous system due to pathologic events during tissue development and represent a condicio sine qua non for tumor development.
Alternative hypotheses
Alternative hypotheses for tumor development include a) tumorigenesis from a pre-existent glial, neuronal, or mesenchymal cell (100); b) tumorigenesis from circulating cells (101); c) tumorigenesis from a stem cell (96, 102, 103 ). a) Tumorigenesis from a pre-existent cell in the nervous system would imply dedifferentiation of mature cells into hemangioblastic progenitor cells which not only has never been demonstrated, but should be expected to be an extraordinarily complex molecular and structural process. Activation of HIF occurs in tissues under hypoxic stress, but is not known to be related to tumorigenesis. Structural analysis of precursor/tumor structures in the nervous system reveal the pathology to evolve from minute poorly differentiated foci into larger lesions with increased maturation (24) , with erythropoiesis occurring only in largest-sized frank tumors (25) . Simply, the abundance of minute structural changes in VHL tissues is explained more easily by an origin from VHL-deficient aberrant cells; furthermore, the most frequent occurrence of precursor structures in nerve root tissue provides a very limited set of candidate cells for tumor development.
b) Circulating bone marrow cells have been implicated in the generation of or contribution to brain tumors (101) . This hypothesis would explain tumor specificity, but require bone marrow hematopoietic cells to be primarily targeted by the second hit. The VHL deficient hemangioblastic progenitor/stem cell is the most primitive form of hemangioblast, originally discovered in the yolk sac (45). To support this hypothesis, it would be necessary to demonstrate presence of these primitive hemangioblastic precursor cells in fetal or adult bone marrow. More difficult to explain, however, would be the principles of organ selectivity and topographic distribution of VHL tumors. In addition, bone marrow pathology is not known to exist in VHL disease. c) Since VHL deficient tumor cells in nervous system have been identified as hemangioblastic progenitor cells, an origin from VHL-deficient stem cells with hemangioblastic differentiation potential certainly deserves consideration. While the role of stem cells in the brain remains controversial, a stem cell origin of brain (and many other) tumors is being increasingly accepted (103). By definition, stem cells are totipotent cells with differentiation potential along multiple (in the brain along astrocytic, oligodendroglial and neuronal) cell lineages which is not the case in VHL disease (tumor specificity). Nevertheless, while the pathogenic cell in VHL nervous system remains bestcharacterized as VHL-deficient hemangioblastic progenitor cell, the second hit could occur in a totipotent stem cell, with VHL inactivation being exclusively permissive for hemangioblastic differentiation. However, the stem cell hypothesis fails to explain organ selectivity and consistent topographical lesion distribution within organs. Also, experimental knock-out of the VHL gene in cell systems has so far not revealed evidence for hemangioblastic differentiation.
In essence, stem cell hypothesis and embryonal rest hypothesis are not entirely exclusive. Like hematopoietic progenitor cells, stem cells are derived from embryonal cells. The key difference is the time of the second hit, VHL inactivation. The stem cell theory would allow for the second hit to occur any time, while the embryonic rest hypothesis postulates the second hit to occur early during tissue development, producing an early and pathologic set of VHL deficient hemangioblastic progenitor cells. It is the embryonic rest hypothesis which most comfortably explains the key arguments presented above.
This modified embryonal rest hypothesis has not been proven, but it most effortlessly explains clinical, pathologic and experimental evidence available so far. Similarly effortlessly it can be applied to any other classic tumor suppressor gene syndrome (e.g. MEN1, neurofibromatosis), with confirmatory literature on record. Thus, VHL disease is a naturally occurring human tumor suppressor gene "model" the unique features of which give insight into the biology of neoplastic disease and cancer.
Conclusion
VHL disease is a classic tumor suppressor gene syndrome caused by VHL gene germline mutation. In the nervous system, the "second hit" -VHL wild-type gene inactivation -induces DASEs which have the potential to develop into benign hemangioblastic tumors. 
